SIGA Technologies reaches final stages of smallpox drug trial

Smallpox continues to threaten various populations.
Smallpox continues to threaten various populations.

SIGA Technologies has reached the final stages of its clinical trial for a drug that could cure small pox. 

The final stages come on the heels of a receipt from the U.S. Food and Drug Administration (FDA) to continue the human study of tecovirimat for concurrence on dosage.

The drug will also work on other orthopoxvirus diseases, such as smallpox.

“We are pleased to receive FDA concurrence on dosage for our clinical safety studies and look forward to the future development and distribution of this critical antiviral,” SIGA CEO Eric Rose said.

The concurrence on dosage gives SIGA the instruction to follow through on phase three, which will include an expanded trial on humans. The drug will be taken orally.

SIDA is a company that develops drugs for medical needs that are serious, yet unmet. The tecovirimat is also known as ST-246.

Organizations in this Story

Siga Technologies, Inc. U.S. Food and Drug Administration (FDA)

Want to get notified whenever we write about any of these organizations ?
Next time we write about any of these organizations, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.